Jazz Pharmaceuticals plc Stock
Price
Target price
€108.15
€108.15
1.070%
1.15
1.070%
€169.26
15:20 / Tradegate
WKN: A1JS1K / Symbol: JAZZ / Name: Jazz Pharma / Stock / Pharmaceuticals / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Jazz Pharmaceuticals plc Stock
Jazz Pharmaceuticals plc gained 1.070% today.
The stock is an absolute favorite of our community with 40 Buy predictions and no Sell predictions.
As a result the target price of 169 € shows a very positive potential of 56.26% compared to the current price of 108.15 € for Jazz Pharmaceuticals plc.
Pros and Cons of Jazz Pharmaceuticals plc in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
B****
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Jazz Pharmaceuticals plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Jazz Pharmaceuticals plc | 1.070% | 4.748% | 6.256% | 4.238% | -8.233% | -31.621% | -3.604% |
| Repligen Corp. | -0.340% | -0.719% | -0.145% | -20.651% | -26.009% | -56.492% | -18.207% |
| Opko Health Inc. | 2.380% | 0.847% | 2.418% | -20.770% | -17.667% | -53.691% | -59.288% |
| Amicus Therapeutics Inc. | 0.780% | 2.400% | 20.755% | -37.864% | -30.055% | -47.107% | -46.218% |
Comments
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Show more
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Royal Bank Of Canada from $145.00 to $151.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $202.00 price target on the stock.
Show more
Ratings data for JAZZ provided by MarketBeat
